#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Marginal zone lymphoma recurrent Factor IX deficiency Biliary neoplasm Castleman's disease Infantile spasms Adrenocortical carcinoma Uveitis Fibrosarcoma Albright's disease Hepatocellular carcinoma Eosinophilic granulomatosis with polyangiitis Thromboangiitis obliterans Antisynthetase syndrome Acquired C1 inhibitor deficiency Erythema multiforme More trials…

    Learn about Rare Diseases

    Lysosomal storage disorder – Basic Information Congenital generalised lipodystrophy – Basic Information Thrombotic thrombocytopenic purpura – Trials in Disease Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Treatment Ornithine transcarbamoylase deficiency – Life with Disease Progressive supranuclear palsy – Life with Disease Retinoblastoma – Diagnostics Hereditary optic atrophy Toxic epidermal necrolysis – Diagnostics Gastrointestinal stromal tumour – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ARTICAINE HYDROCHLORIDE Voxelotor Loncastuximab Tesirine Levosimendan Resmetirom AZD1163 Av-Ec2023 Calcipotriol Estradiol Valerate Clindamycin Gliclazide SRSD107 Doxazosin ALLERGEN EXTRACTS Colestyramine Elritercept Fulvestrant Histamine Hydrochloride Munc-Cd34 Atl001 More therapies…

    Learn about Your Condition

    Cervix carcinoma recurrent Sarcoidosis Round cell liposarcoma Septic shock Mast cell activation syndrome Hypophosphatasia Hyperhidrosis Diminished ovarian reserve Obstructive pancreatitis Wheezing Duchenne muscular dystrophy Andersen-Tawil syndrome Multifocal motor neuropathy Coagulopathy Prostatitis Escherichia coli More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Ovarian cancer recurrent

  • Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Bevacizumab
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    Austria Belgium Czechia Denmark Finland France +6

  • Evaluation of Raludotatug Deruxtecan With Carboplatin, Paclitaxel, or Bevacizumab in Relapsed High-grade Serous Ovarian, Peritoneal, or Fallopian Tube Cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Raludotatug Deruxtecan
    • Bevacizumab
    • Carboplatin
    Spain

  • Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Peritoneal cancer index
    • Endometrial cancer
    Investigated Drugs:
    • Sarilumab
    • Ubamatamab
    • Cemiplimab
    Belgium France Italy The Netherlands Spain

  • Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Codeine Phosphate
    • H2-Receptor Antagonists
    Austria Belgium Czechia Denmark Finland France +8

  • Study Comparing Olaparib and Chemotherapy for Patients with Recurrent Ovarian Cancer After Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Cisplatin
    Italy

  • Study of Olaparib for Patients with Recurrent Ovarian Cancer Without BRCA Gene Mutations

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer recurrent
    Investigated Drugs:
    • Olaparib
    Italy
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!